Bristol Myers Squibb is diversifying in oncology with the $4.8 billion acquisition of Mirati Therapeutics, a company that brings a commercialized drug for an elusive target and a pipeline of compounds ...
SAN DIEGO, April 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced initial preclinical results evaluating its investigational ...
SAN DIEGO, March 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced it will present initial preclinical data on the Company's ...
Tango Therapeutics, a biotech company focused on synthetic lethality and PRMT5 inhibition, has two PRMT5 inhibitors in clinical development. Tango's shares spiked after positive data from Mirati ...
Bristol Myers Squibb BMY announced that it will acquire commercial-stage oncology company Mirati Therapeutics, Inc. MRTX for $58.00 per share in cash, amounting to a total equity value of $4.8 billion ...
Bristol-Myers Squibb Co. agreed to buy drugmaker Mirati Therapeutics for $4.8 billion to expand its aging portfolio of cancer drugs. Mirati shareholders will receive $58 a share in cash, the companies ...
Bristol-Myers Squibb Co. agreed to buy cancer drugmaker Mirati Therapeutics Inc. for $4.8 billion Sunday, a price that disappointed investors after reported interest from rival Sanofi. Mirati ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results